Short answer
Lilly (Eli) (LLY) filed its Q1 2025 10-Q quarterly report on May 1, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $12.7B (up 45.2% year over year) with net income of $2.8B.
Q1 2025 key financials · XBRL
- Revenue
- $12.7B
- +45.2% YoY
- Net income
- $2.8B
- +23.0% YoY
- EPS (diluted)
- $3.06
- +23.4% YoY
Source: XBRL data from the Lilly (Eli) (LLY) Q1 2025 10-Q on SEC EDGAR. USD.
Lilly (Eli) Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash and cash equivalents $3.09B as of Mar 31, 2025 vs $3.27B Dec 31, 2024
- Total debt $38.52B up $4.87B from $33.64B Dec 31, 2024, driven by $6.5B notes issued and Scorpion acquisition
- Share repurchases $1.20B executed in Q1 2025 under $15B program, $13.80B remaining
- Dividends paid $1.35B or $1.50/share in Q1 2025
- Capital expenditures increasing due to global manufacturing investments and contract manufacturing agreements up to $8B potential liability
Risk Factors
- New acquisition risk: $1,571.7 million acquired IPR&D charge from Scorpion PI3Kα inhibitor program STX-478 acquisition
- Updated tax risk: effective tax rate increased to 20.2% from 11.6%, driven by non-deductible acquired IPR&D charge
- Regulatory/legal risk: amendment with Boehringer Ingelheim caused $370 million one-time Jardiance collaboration benefit
- Operational risk: marketing expenses up 26% driven by promotion of ongoing and future product launches impacting near-term costs
- Financial risk: strong liquidity supported by cash, cash equivalents, operating cash flow, and access to borrowings to fund capital needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Lilly (Eli) quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.